Skip to content
HowShorted

Cardiff Oncology, Inc. short interest in 2021

In 2021, Cardiff Oncology, Inc.'s disclosed short interest ran from 16.55% of shares outstanding on 15 Jan 2021 to 7.04% on 31 Dec 2021, a change of -9.51 percentage points. The year's high was 18.36% on 29 Jan 2021 and its low 6.36% on 15 Nov 2021, averaging 9.17% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.25 days on 29 Oct 2021. Full history: Cardiff Oncology, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Cardiff Oncology, Inc. in 2021

2021 in figures

Start of year
16.55% (15 Jan 2021)
End of year
7.04% (31 Dec 2021)
Change
-9.51 pp
High
18.36% (29 Jan 2021)
Low
6.36% (15 Nov 2021)
Average
9.17%
Highest days to cover
9.25 (29 Oct 2021)
SEC filings marked
8

Every report in 2021

Cardiff Oncology, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202116.55%7.02
29 Jan 202118.36%1.56
12 Feb 202116.85%3.00
26 Feb 202115.17%4.6310-K filed, results (8-K)
15 Mar 202115.30%6.49
31 Mar 20217.49%2.53
15 Apr 20217.21%4.49
30 Apr 20217.37%5.92
14 May 20218.24%4.3510-Q filed, results (8-K)
28 May 20217.42%4.79
15 Jun 20216.91%6.51
30 Jun 20218.64%3.37
15 Jul 20217.69%4.32
30 Jul 20217.13%3.75
13 Aug 20217.19%4.3610-Q filed, results (8-K)
31 Aug 20218.02%4.73
15 Sep 20216.51%1.00
30 Sep 20216.73%4.32
15 Oct 20216.77%6.15
29 Oct 20216.89%9.25
15 Nov 20216.36%5.6010-Q filed, results (8-K)
30 Nov 20217.45%1.09
15 Dec 20216.76%5.44
31 Dec 20217.04%5.08

See also: Cardiff Oncology, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.